Latest news with #andSpecialMeetingof
Business Wire
2 hours ago
- Business
- Business Wire
Sherritt Reports Shareholder Meeting Results, Board Appointments and Committee Updates
TORONTO--(BUSINESS WIRE)--Sherritt International Corporation ('Sherritt' or the 'Corporation') (TSX:S) today announced the voting results of its 2025 Annual and Special Meeting of Shareholders held June 10, 2025, the appointment of John Ewing to the Board of Directors (the 'Board'), the appointments of Leon Binedell as Executive Chairman and Shelley Brown as Lead Independent Director, respectively, and other governance updates. 2025 Annual and Special Meeting of Shareholders Voting Results A total of 283,623,833 common shares or 57.15% of Sherritt's issued and outstanding common shares were represented in person or by proxy at the meeting. A majority of the votes were cast in favour of all items of business put forth at the meeting, including the re-appointment of Deloitte LLP as external auditors, amendments to the Corporation's stock option plan and the non-binding advisory resolution known as 'Say on Pay.' Election of Directors Each of the six director nominees standing for election was elected as a director of Sherritt to serve until the next annual general meeting of the company or until his or her successor is elected or appointed: The full Report of Voting Results has been filed on SEDAR+ at Director Appointment and Continued Commitment to Board Renewal To fill the vacancy on the Board resulting from Sir Richard Lapthorne's retirement as announced on June 9, 2025, and consistent with the Corporation's ongoing commitment to good governance and Board renewal, following the meeting, the Board appointed John Ewing, bringing the total number of directors to seven. A biography for Mr. Ewing is provided below. The Board intends to continue the Board renewal process with the appointment of at least one additional independent director, preferably with mining engineering expertise and the potential to assume a leadership position on the Board, by December 31, 2025. All directors are independent within the meaning of applicable securities laws, other than Leon Binedell who also serves as President and CEO of the Corporation. John Ewing is the nominee of Sherritt shareholder Ewing Morris & Co. Investment Partners Ltd. ('Ewing Morris'), and Richard Moat is the nominee of Sherritt shareholder Kyma Capital Limited. Board Leadership and Committee Updates In connection with the reconstitution of the Board, the Corporation announces that Leon Binedell has been appointed Executive Chairman, following the retirement of former Chairman Sir Richard Lapthorne. Shelley Brown, an independent director of Sherritt since August 2024, has been named Lead Independent Director. The Board committees have also been reconstituted to better align with the expertise of the new directors, including the appointment of Mr. Ewing to the Reserves, Operations and Capital Committee and Mr. Moat to the Audit Committee. Additionally, the former HR Committee and the former Nominating and Corporate Governance Committee have been consolidated into a single committee. This streamlining reflects the Corporation's commitment to enhancing Board efficiency, while reducing management's administrative burden to support a greater focus on operational priorities. Sherritt shareholders SC2 Inc. ('SC2') and Ewing Morris have expressed their alignment with the Corporation's ongoing Board renewal process and have committed to supporting Sherritt's director nominees through the 2026 annual meeting of shareholders. 'I believe in Sherritt's potential,' said John Ewing, Sherritt Director and Co-Founder of Ewing Morris. 'I look forward to collaborating with my colleagues on the Board to help Sherritt achieve new milestones and deliver long-term value for all stakeholders.' 'We are encouraged with the progress in Sherritt's Board renewal process,' said Casey McKenzie, President, SC2. 'We recognize the Corporation's potential and look forward to supporting management in driving continued improvements in performance.' Leon Binedell, Sherritt Executive Chairman added: 'On behalf of Sherritt, I would like to thank Ewing Morris, SC2, and our broader shareholder base for their engagement and ongoing support. In addition, Sherritt and Seablinc look forward to re-establishing a normal commercial relationship. Over the past few years, we have worked with determination to position Sherritt for sustainable growth and value creation. I am confident that John will make valuable contributions to the Board and the Corporation as we continue to strengthen and build upon this foundation.' About John Ewing Mr. Ewing is Chief Investment Officer of Ewing Morris & Co. Investment Partners. He co-founded the firm in June 2011 with Darcy Morris. Mr. Ewing graduated with distinction from the University of Guelph with an Honours Bachelor of Science in Engineering degree and a Minor in Business Administration. About Sherritt Sherritt is a world leader in using hydrometallurgical processes to mine and refine nickel and cobalt – metals deemed critical for the energy transition. Sherritt's Moa Joint Venture has an estimated mine life of approximately 25 years and is advancing an expansion program focused on increasing annual MSP production by 20% of contained nickel and cobalt. The Corporation's Power division, through its ownership in Energas, is the largest independent energy producer in Cuba with installed electrical generating capacity of 506 MW, representing approximately 10% of the national electrical generating capacity in Cuba. The Energas facilities are comprised of two combined cycle plants that produce low-cost electricity from one of the lowest carbon emitting sources of power in Cuba. Sherritt's common shares are listed on the Toronto Stock Exchange under the symbol 'S'. FORWARD-LOOKING STATEMENTS Certain statements and other information included in this press release constitute 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking statements') under applicable securities laws (such statements are often accompanied by words such as 'anticipate', 'forecast', 'expect', 'believe', 'may', 'will', 'should', 'estimate', 'intend' or other similar words). All statements in this press release, other than those relating to historical information, are forward-looking statements, including, but not limited statements regarding strategies, plans and estimated production amounts resulting from expansion of mining operations at the Moa Joint Venture. The Corporation cautions readers of this press release not to place undue reliance on any forward-looking statement as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed in the forward-looking statements. The key risks and uncertainties should be considered in conjunction with the risk factors described in the Corporation's other documents filed with the Canadian securities authorities, including without limitation the 'Managing Risk' section of the Management's Discussion and Analysis for the three months ended March 31, 2025 and the Annual Information Form of the Corporation dated March 24, 2025 for the period ending December 31, 2024, which is available on SEDAR+ at The forward-looking information and statements contained in this press release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any oral or written forward-looking information or statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement.
Cision Canada
20-05-2025
- Business
- Cision Canada
COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of Transparency Under Current Leadership
Details How MediPharm Labs is Hemorrhaging Money at an Alarming Rate and is on Pace to Run Out of Cash by November 2025 Exorbitant Executive Compensation Packages Despite Persistent Losses Demonstrate a Board and Management Team Misaligned with Shareholders' Best Interests Board Cannot Be Trusted After Costing Shareholders $1 Billion Nominates Six Highly Qualified Director Candidates – John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters – to Cure MediPharm Labs Before It's Too Late Nominees Bring Significant Turnaround, M&A, and Operational Expertise Alongside Fresh Perspectives to Restore Value and Accountability at MediPharm Labs TORONTO, May 20, 2025 /CNW/ -- Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today announced that it has filed an amended and restated information circular (the "Circular") in connection with its intention to nominate six highly qualified director candidates to MediPharm's Board of Directors (the "Board") at the Company's upcoming 2025 Annual and Special Meeting of Shareholders to be held on June 16, 2025 (the "Annual Meeting"). Additionally, Apollo Capital launched a campaign website at where shareholders can review the facts, understand what's at stake, and learn how to protect the value of their investment. The website details Apollo Capital's 5-Pillar Plan to restore value to MediPharm Labs, as well as specific actions that the nominees would take in their first 100 days of service on the Board. The 5-Pillar Plan includes: Replace Failed Leadership with Aligned Executives Implement Financial Discipline & Strategic Review Retain Strategic Assets for Long-Term Shareholder Value Unlock International Medical Growth Restore Trust Through Transparency and Good Governance The Circular and website present a clear and compelling case regarding MediPharm Labs' severe underperformance, reckless strategic missteps, and alarming destruction of shareholder value, which have placed the company in serious jeopardy while the management team receives exorbitant pay packages. These failures have cost shareholders $1 billion, and reduced the Company's cash position to just $8 million as of March 31, 2025 – on pace to reach zero by November 2025. The Circular and website provide information about Apollo Capital's nominees – John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters – who are accomplished business leaders committed to openness and transparency in their dialogue with MediPharm Labs shareholders. In particular, they are prepared to answer any questions or address any concerns shareholders might have – even if they are difficult. This is a stark contrast to MediPharm Lab's current Board and management team, which has avoided answering for their failures, including not holding a shareholder call for three quarters and not answering any of the questions Apollo put forth before the first quarter 2025 financial results call. Apollo Capital believes a wholesale Board change at MediPharm Labs is the only path forward, and that shareholders must act now before it's too late. At , shareholders can also sign up for important campaign updates. To access Apollo Capital's Circular and related proxy materials, including a proxy or voting instruction form, visit SEDAR+ at Contacts For Shareholders: Carson Proxy North American Toll-Free Phone: 1-800-530-5189 Local or Text Message: 416-751-2066 (collect calls accepted) E: [email protected] For Media: Nathaniel Garnick/Mark Semer/Grace Cartwright Gasthalter & Co. +1 (212) 257-4170 [email protected] Legal Disclosures Information in Support of Public Broadcast Exemption under Canadian Law In connection with the Annual Meeting, Apollo Capital has filed an amended and restated dissident information circular (the "Circular") in compliance with applicable corporate and securities laws. Apollo Capital has provided in, or incorporated by reference into, this press release the disclosure required under section 9.2(4) of NI 51-102 – Continuous Disclosure Obligations ("NI 51-102") and the corresponding exemption under the Business Corporations Act (Ontario), and has filed the Circular, available under MediPharm's profile on SEDAR+ at The Circular contains disclosure prescribed by applicable corporate law and disclosure required under section 9.2(6) of NI 51-102 in respect of Apollo Capital's director nominees, in accordance with corporate and securities laws applicable to public broadcast solicitations. The Circular is hereby incorporated by reference into this press release and is available under MediPharm's profile on SEDAR+ at The registered office of the Company is 151 John Street, Barrie, Ontario, Canada L4N 2L1. SHAREHOLDERS OF MEDIPHARM ARE URGED TO READ THE CIRCULAR CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and shareholders are able to obtain free copies of the Circular and any amendments or supplements thereto and further proxy circulars at no charge under MediPharm's profile on SEDAR+ at In addition, shareholders are also able to obtain free copies of the Circular and other relevant documents by contacting Apollo Capital's proxy solicitor, Carson Proxy Advisors Ltd. ("Carson Proxy") at 1-800-530-5189, local (collect outside North America): 416-751-2066 or by email at [email protected]. Proxies may be revoked in accordance with subsection 110(4) of the Business Corporations Act (Ontario) by a registered shareholder of Company shares: (a) by completing and signing a valid proxy bearing a later date and returning it in accordance with the instructions contained in the accompanying form of proxy; (b) by depositing an instrument in writing executed by the shareholder or by the shareholder's attorney authorized in writing; (c) by transmitting by telephonic or electronic means a revocation that is signed by electronic signature in accordance with applicable law, as the case may be: (i) at the registered office of the Company at any time up to and including the last business day preceding the day the Annual Meeting or any adjournment or postponement of the Annual Meeting is to be held, or (ii) with the chair of the Annual Meeting on the day of the Annual Meeting or any adjournment or postponement of the Annual Meeting; or (d) in any other manner permitted by law. In addition, proxies may be revoked by a non-registered holder of Company shares at any time by written notice to the intermediary in accordance with the instructions given to the non-registered holder by its intermediary. It should be noted that revocation of proxies or voting instructions by a non-registered holder can take several days or even longer to complete and, accordingly, any such revocation should be completed well in advance of the deadline prescribed in the form of proxy or voting instruction form to ensure it is given effect in respect of the Annual Meeting. The costs incurred in the preparation and mailing of any circular or proxy solicitation by Apollo Capital and any other participants named herein will be borne directly and indirectly by Apollo Capital. However, to the extent permitted under applicable law, Apollo Capital intends to seek reimbursement from the Company of all expenses incurred in connection with the solicitation of proxies for the election of its director nominees at the Annual Meeting. This press release and any solicitation made by Apollo Capital is, or will be, as applicable, made by such parties, and not by or on behalf of the management of the Company. Proxies may be solicited by proxy circular, mail, telephone, email or other electronic means, as well as by newspaper or other media advertising and in person by managers, directors, officers and employees of Apollo Capital who will not be specifically remunerated therefor. In addition, Apollo Capital may solicit proxies by way of public broadcast, including press release, speech or publication and any other manner permitted under applicable Canadian laws, and may engage the services of one or more agents and authorize other persons to assist it in soliciting proxies on their behalf. Apollo Capital has entered into an agreement with Carson Proxy Advisors ("Carson Proxy") for solicitation and advisory services in connection with the solicitation of proxies for the Meeting, for which Carson Proxy will receive a fee not to exceed $250,000, together with reimbursement for reasonable and out-of-pocket expenses. Apollo Capital has also engaged Gasthalter & Co. LP ("G&Co") to act as communications consultant to provide Apollo Capital with certain communications, public relations and related services, for which G&Co will receive a minimum fee of US$75,000 in addition to a performance fee of US$250,000 in the event that Apollo Capital's nominees make up a majority of the Board following the Annual Meeting, plus excess fees, related costs and expenses. No member of Apollo Capital nor any of their associates or affiliates has or has had any material interest, direct or indirect, in any transaction since the beginning of the Company's last completed financial year or in any proposed transaction that has materially affected or will or would materially affect the Company or any of the Company's affiliates. No member of Apollo Capital nor any of their associates or affiliates has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Annual Meeting, other than setting the number of directors, the election of directors, the appointment of auditors and the approval of the ordinary resolution approving, among other things, the Company's amended and restated equity incentive plan dated May 8, 2025 and the unallocated awards available thereunder. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward‐looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward‐looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward‐looking statements. These statements are based on current expectations of Apollo Capital and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. All forward-looking statements contained herein are made only as of the date hereof and Apollo Capital disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which Apollo Capital hereafter becomes aware, except as required by applicable law.
Yahoo
20-05-2025
- Business
- Yahoo
COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of Transparency Under Current Leadership
Launches Campaign Website at Which Articulates 5-Pillar Plan to Rebuild Company Details How MediPharm Labs is Hemorrhaging Money at an Alarming Rate and is on Pace to Run Out of Cash by November 2025 Exorbitant Executive Compensation Packages Despite Persistent Losses Demonstrate a Board and Management Team Misaligned with Shareholders' Best Interests Board Cannot Be Trusted After Costing Shareholders $1 Billion Nominates Six Highly Qualified Director Candidates – John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters – to Cure MediPharm Labs Before It's Too Late Nominees Bring Significant Turnaround, M&A, and Operational Expertise Alongside Fresh Perspectives to Restore Value and Accountability at MediPharm Labs URGES SHAREHOLDERS TO DISREGARD MEDIPHARM'S GREEN PROXY CARD AND VOTE THE GOLD PROXY CARD "FOR" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES TORONTO, May 20, 2025 /CNW/ -- Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today announced that it has filed an amended and restated information circular (the "Circular") in connection with its intention to nominate six highly qualified director candidates to MediPharm's Board of Directors (the "Board") at the Company's upcoming 2025 Annual and Special Meeting of Shareholders to be held on June 16, 2025 (the "Annual Meeting"). Additionally, Apollo Capital launched a campaign website at where shareholders can review the facts, understand what's at stake, and learn how to protect the value of their investment. The website details Apollo Capital's 5-Pillar Plan to restore value to MediPharm Labs, as well as specific actions that the nominees would take in their first 100 days of service on the Board. The 5-Pillar Plan includes: Replace Failed Leadership with Aligned Executives Implement Financial Discipline & Strategic Review Retain Strategic Assets for Long-Term Shareholder Value Unlock International Medical Growth Restore Trust Through Transparency and Good Governance The Circular and website present a clear and compelling case regarding MediPharm Labs' severe underperformance, reckless strategic missteps, and alarming destruction of shareholder value, which have placed the company in serious jeopardy while the management team receives exorbitant pay packages. These failures have cost shareholders $1 billion, and reduced the Company's cash position to just $8 million as of March 31, 2025 – on pace to reach zero by November 2025. The Circular and website provide information about Apollo Capital's nominees – John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters – who are accomplished business leaders committed to openness and transparency in their dialogue with MediPharm Labs shareholders. In particular, they are prepared to answer any questions or address any concerns shareholders might have – even if they are difficult. This is a stark contrast to MediPharm Lab's current Board and management team, which has avoided answering for their failures, including not holding a shareholder call for three quarters and not answering any of the questions Apollo put forth before the first quarter 2025 financial results call. Apollo Capital believes a wholesale Board change at MediPharm Labs is the only path forward, and that shareholders must act now before it's too late. At shareholders can also sign up for important campaign updates. To access Apollo Capital's Circular and related proxy materials, including a proxy or voting instruction form, visit SEDAR+ at Contacts For Shareholders:Carson ProxyNorth American Toll-Free Phone: 1-800-530-5189Local or Text Message: 416-751-2066 (collect calls accepted)E: info@ For Media:Nathaniel Garnick/Mark Semer/Grace CartwrightGasthalter & Co.+1 (212) 257-4170CureMediPharm@ Legal Disclosures Information in Support of Public Broadcast Exemption under Canadian Law In connection with the Annual Meeting, Apollo Capital has filed an amended and restated dissident information circular (the "Circular") in compliance with applicable corporate and securities laws. Apollo Capital has provided in, or incorporated by reference into, this press release the disclosure required under section 9.2(4) of NI 51-102 – Continuous Disclosure Obligations ("NI 51-102") and the corresponding exemption under the Business Corporations Act (Ontario), and has filed the Circular, available under MediPharm's profile on SEDAR+ at The Circular contains disclosure prescribed by applicable corporate law and disclosure required under section 9.2(6) of NI 51-102 in respect of Apollo Capital's director nominees, in accordance with corporate and securities laws applicable to public broadcast solicitations. The Circular is hereby incorporated by reference into this press release and is available under MediPharm's profile on SEDAR+ at The registered office of the Company is 151 John Street, Barrie, Ontario, Canada L4N 2L1. SHAREHOLDERS OF MEDIPHARM ARE URGED TO READ THE CIRCULAR CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and shareholders are able to obtain free copies of the Circular and any amendments or supplements thereto and further proxy circulars at no charge under MediPharm's profile on SEDAR+ at In addition, shareholders are also able to obtain free copies of the Circular and other relevant documents by contacting Apollo Capital's proxy solicitor, Carson Proxy Advisors Ltd. ("Carson Proxy") at 1-800-530-5189, local (collect outside North America): 416-751-2066 or by email at info@ Proxies may be revoked in accordance with subsection 110(4) of the Business Corporations Act (Ontario) by a registered shareholder of Company shares: (a) by completing and signing a valid proxy bearing a later date and returning it in accordance with the instructions contained in the accompanying form of proxy; (b) by depositing an instrument in writing executed by the shareholder or by the shareholder's attorney authorized in writing; (c) by transmitting by telephonic or electronic means a revocation that is signed by electronic signature in accordance with applicable law, as the case may be: (i) at the registered office of the Company at any time up to and including the last business day preceding the day the Annual Meeting or any adjournment or postponement of the Annual Meeting is to be held, or (ii) with the chair of the Annual Meeting on the day of the Annual Meeting or any adjournment or postponement of the Annual Meeting; or (d) in any other manner permitted by law. In addition, proxies may be revoked by a non-registered holder of Company shares at any time by written notice to the intermediary in accordance with the instructions given to the non-registered holder by its intermediary. It should be noted that revocation of proxies or voting instructions by a non-registered holder can take several days or even longer to complete and, accordingly, any such revocation should be completed well in advance of the deadline prescribed in the form of proxy or voting instruction form to ensure it is given effect in respect of the Annual Meeting. The costs incurred in the preparation and mailing of any circular or proxy solicitation by Apollo Capital and any other participants named herein will be borne directly and indirectly by Apollo Capital. However, to the extent permitted under applicable law, Apollo Capital intends to seek reimbursement from the Company of all expenses incurred in connection with the solicitation of proxies for the election of its director nominees at the Annual Meeting. This press release and any solicitation made by Apollo Capital is, or will be, as applicable, made by such parties, and not by or on behalf of the management of the Company. Proxies may be solicited by proxy circular, mail, telephone, email or other electronic means, as well as by newspaper or other media advertising and in person by managers, directors, officers and employees of Apollo Capital who will not be specifically remunerated therefor. In addition, Apollo Capital may solicit proxies by way of public broadcast, including press release, speech or publication and any other manner permitted under applicable Canadian laws, and may engage the services of one or more agents and authorize other persons to assist it in soliciting proxies on their behalf. Apollo Capital has entered into an agreement with Carson Proxy Advisors ("Carson Proxy") for solicitation and advisory services in connection with the solicitation of proxies for the Meeting, for which Carson Proxy will receive a fee not to exceed $250,000, together with reimbursement for reasonable and out-of-pocket expenses. Apollo Capital has also engaged Gasthalter & Co. LP ("G&Co") to act as communications consultant to provide Apollo Capital with certain communications, public relations and related services, for which G&Co will receive a minimum fee of US$75,000 in addition to a performance fee of US$250,000 in the event that Apollo Capital's nominees make up a majority of the Board following the Annual Meeting, plus excess fees, related costs and expenses. No member of Apollo Capital nor any of their associates or affiliates has or has had any material interest, direct or indirect, in any transaction since the beginning of the Company's last completed financial year or in any proposed transaction that has materially affected or will or would materially affect the Company or any of the Company's affiliates. No member of Apollo Capital nor any of their associates or affiliates has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Annual Meeting, other than setting the number of directors, the election of directors, the appointment of auditors and the approval of the ordinary resolution approving, among other things, the Company's amended and restated equity incentive plan dated May 8, 2025 and the unallocated awards available thereunder. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward‐looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward‐looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward‐looking statements. These statements are based on current expectations of Apollo Capital and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. All forward-looking statements contained herein are made only as of the date hereof and Apollo Capital disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which Apollo Capital hereafter becomes aware, except as required by applicable law. View original content to download multimedia: SOURCE Apollo Technology Capital Corporation View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
06-05-2025
- Business
- Hamilton Spectator
Barrick Announces Name Change to BARRICK MINING CORPORATION and Election of Directors
TORONTO, May 06, 2025 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:GOLD1)(TSX:ABX) ('Barrick' or the 'Company') today announced that it has completed its name change to Barrick Mining Corporation and « Société minière Barrick » in French, following receipt of shareholder approval at its Annual and Special Meeting of Shareholders held earlier today. The Barrick common shares will commence trading under the Company's new name on the New York Stock Exchange and the Toronto Stock Exchange at the start of trading on May 9, 2025. In connection with the name change, the ticker symbol for the Barrick common shares listed on the New York Stock Exchange will be changed to 'B', effective as of the start of trading on May 9, 2025. The Barrick common shares will continue to trade under the 'ABX' ticker symbol on the Toronto Stock Exchange. The new CUSIP number for the Barrick common shares effective at the start of trading on May 9, 2025 will be 06849F108. The Company also today announced that the nominees put forward in the Information Circular for the 2025 Annual and Special Meeting of Shareholders were elected as directors of Barrick. Detailed voting results of the business considered at the 2025 Annual and Special Meeting of Shareholders are set out below. Voting results for the election of each of the directors are as follows: Voting results for the resolution approving the appointment of the auditor are as follows: Voting results for the advisory resolution on executive compensation are as follows: Voting results for the special resolution approving the name change are as follows: Enquiries: Investor and Media Relations Kathy du Plessis +44 20 7557 7738 Email: barrick@ Website: Endnote 1 The ticker symbol for the Barrick common shares listed on the New York Stock Exchange is changing from 'GOLD' to 'B', effective at the start of trading on May 9, 2025. The Barrick common shares will continue to trade under the 'ABX' ticker symbol on the Toronto Stock Exchange. The new CUSIP number for the Barrick common shares effective at the start of trading on May 9, 2025 will be 06849F108. Cautionary Statement on Forward-Looking Information Certain information contained in this press release constitutes 'forward-looking statements'. All statements, other than statements of historical fact, are forward-looking statements. The words 'build', 'strategy', 'commitment', 'develop', 'replenish', 'secure', 'transform', 'continue', 'expand', 'grow', 'expand', 'extension', 'invest', 'will' and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to: Barrick's future plans and the timing for such plans, growth potential, financial strength, investments and overall strategy; and expectations regarding future price assumptions, financial performance, shareholder returns and other outlook or guidance. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Barrick as at the date of this press release in light of management's experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Many of these uncertainties and contingencies can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Readers are cautioned that forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements. Specific reference is made to the most recent Form 40-F/Annual Information Form on file with the SEC and Canadian provincial securities regulatory authorities for a more detailed discussion of some of the factors underlying forward-looking statements and the risks that may affect Barrick's ability to achieve the expectations set forth in the forward-looking statements contained in this press release. We disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
